Status:
COMPLETED
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
Lead Sponsor:
Takeda
Conditions:
Hypertension
Eligibility:
All Genders
Brief Summary
The purpose of this study is to gain an understanding of the actual use of candesartan cilexetil (Blopress) in patients with hypertension, and to examine the changes in parameters such as blood pressu...
Detailed Description
This special drug use surveillance was planned to gain an understanding of the actual use of candesartan cilexetil in the new anti-hypertensive treatment environment where angiotensin receptor blocker...
Eligibility Criteria
Inclusion
- Hypertensive patients
Exclusion
- Inpatients
- Patients under dialysis (planned)
- Patients with a history of coronary artery disease/cerebrovascular disorder within 6 months
- Patients with ≥ class III of the New York Heart Association (NYHA) classification functional classification of heart failure
- Patients that have been prescribed with candesartan (this drug/Ecard/Unisia) in the past
- Patients who are pregnant or may possibly become pregnant
Key Trial Info
Start Date :
June 13 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 25 2013
Estimated Enrollment :
18113 Patients enrolled
Trial Details
Trial ID
NCT02211638
Start Date
June 13 2011
End Date
April 25 2013
Last Update
November 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Osaka, Japan